(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -2.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Arcus Biosciences's revenue in 2026 is $236,000,000.On average, 13 Wall Street analysts forecast RCUS's revenue for 2026 to be $11,700,425,715, with the lowest RCUS revenue forecast at $862,803,891, and the highest RCUS revenue forecast at $29,053,600,422. On average, 13 Wall Street analysts forecast RCUS's revenue for 2027 to be $17,238,469,584, with the lowest RCUS revenue forecast at $0, and the highest RCUS revenue forecast at $46,808,997,702.
In 2028, RCUS is forecast to generate $28,311,538,766 in revenue, with the lowest revenue forecast at $9,851,811,779 and the highest revenue forecast at $78,012,061,462.